Mirum Pharmaceuticals Inc [MIRM] stock is trading at $47.13, up 6.36%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MIRM shares have gain 4.66% over the last week, with a monthly amount drifted -10.57%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mirum Pharmaceuticals Inc [NASDAQ: MIRM] stock has seen the most recent analyst activity on April 17, 2024, when Stifel initiated its Buy rating and assigned the stock a price target of $48. Previously, H.C. Wainwright reaffirmed its Buy rating on December 18, 2023, and dropped its price target to $58. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $60 on November 13, 2023. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $50 as its price target on October 24, 2023. In a note dated September 20, 2023, JMP Securities initiated an Mkt Outperform rating and provided a target price of $70 on this stock.
Mirum Pharmaceuticals Inc [MIRM] stock has fluctuated between $23.14 and $54.23 over the past year. Currently, Wall Street analysts expect the stock to reach $70 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $47.13 at the most recent close of the market. An investor can expect a potential return of 48.53% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
Mirum Pharmaceuticals Inc [NASDAQ:MIRM] reported sales of 336.89M for the trailing twelve months, which represents a growth of 42.93%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -0.26%, Pretax Profit Margin comes in at -0.26%, and Net Profit Margin reading is -0.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.38 and Total Capital is -0.16. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 44.74 points at the first support level, and at 42.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.58, and for the 2nd resistance point, it is at 50.04.
Ratios To Look Out For
For context, Mirum Pharmaceuticals Inc’s Current Ratio is 3.10. In addition, the Quick Ratio stands at 2.93 and the Cash Ratio stands at 1.76. Considering the valuation of this stock, the price to sales ratio is 6.86, the price to book ratio is 10.10.
Transactions by insiders
Recent insider trading involved Howe Jolanda, SVP, GLOBAL CONTROLLER, that happened on Mar 18 ’25 when 2415.0 shares were sold. SVP, GLOBAL CONTROLLER, Howe Jolanda completed a deal on Mar 17 ’25 to sell 57606.0 shares. Meanwhile, PRESIDENT AND COO Radovich Peter sold 7879.0 shares on Mar 17 ’25.
